blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2422782

EP2422782 - METHODS OF USING SUSTAINED RELEASE AMINOPYRIDINE COMPOSITIONS [Right-click to bookmark this link]
Former [2012/09]Methods of Using Sustained Release Aminopyridine Compositions
[2021/02]
StatusThe application is deemed to be withdrawn
Status updated on  03.09.2021
Database last updated on 11.04.2026
FormerGrant of patent is intended
Status updated on  16.12.2020
FormerExamination is in progress
Status updated on  29.11.2017
Most recent event   Tooltip03.09.2021Application deemed to be withdrawnpublished on 06.10.2021  [2021/40]
Applicant(s)For all designated states
Acorda Therapeutics, Inc.
420 Saw Mill River Road
Ardsley, NY 10502 / US
[2013/07]
Former [2012/09]For all designated states
Acorda Therapeutics, Inc.
15 Skyline Drive
Hawthorne NY 10531 / US
Inventor(s)01 / Blight, Andrew R.
10 Oskar Drive
Mahopac, NY 10541 / US
02 / Cohen, Ron
246 Harriman Road
Irvington, NY 10533 / US
 [2012/09]
Representative(s)Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
[N/P]
Former [2012/09]Carpmaels & Ransford
One Southampton Row London
WC1B 5HA / GB
Application number, filing date11168901.411.04.2005
[2012/09]
Priority number, dateUS20040560894P09.04.2004         Original published format: US 560894 P
US2005010255908.04.2005         Original published format: US 102559
[2012/09]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP2422782
Date:29.02.2012
Language:EN
[2012/09]
Search report(s)(Supplementary) European search report - dispatched on:EP01.02.2012
ClassificationIPC:A61P25/00
[2020/09]
CPC:
A61K31/4409 (EP,US); A61K31/435 (EP,US); A61K31/44 (EP,US);
A61K9/20 (US); A61P17/02 (EP); A61P19/08 (EP);
A61P21/00 (EP); A61P25/00 (EP); A61P25/28 (EP);
A61P43/00 (EP) (-)
Former IPC [2012/09]A61K31/44
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2012/09]
Extension statesAL29.08.2012
BA29.08.2012
HR29.08.2012
LV29.08.2012
MK29.08.2012
YU29.08.2012
TitleGerman:VERFAHREN ZUR VERWENDUNG VON AMINOPYRIN-ZUSAMMENSETZUNGEN MIT VERZÖGERTER FREISETZUNG[2021/02]
English:METHODS OF USING SUSTAINED RELEASE AMINOPYRIDINE COMPOSITIONS[2021/02]
French:UTILISATION DE COMPOSITIONS D'AMINOPYRIDINE À LIBÉRATION SOUTENUE[2021/02]
Former [2012/09]Verfahren zur Verwendung von Aminopyrin-Zusammensetzungen mit verzögerter Freisetzung
Former [2012/09]Methods of Using Sustained Release Aminopyridine Compositions
Former [2012/09]Utilisation de compositions d'aminopyridine à libération soutenue
Examination procedure29.08.2012Examination requested  [2012/41]
04.10.2013Despatch of a communication from the examining division (Time limit: M06)
11.04.2014Reply to a communication from the examining division
28.05.2015Despatch of a communication from the examining division (Time limit: M06)
21.03.2016Reply to a communication from the examining division
11.10.2017Cancellation of oral proceeding that was planned for 17.11.2017
24.10.2017Observations by third parties
17.11.2017Date of oral proceedings (cancelled)
20.11.2017Despatch of a communication from the examining division (Time limit: M06)
06.09.2018Reply to a communication from the examining division
17.01.2019Despatch of a communication from the examining division (Time limit: M06)
01.11.2019Reply to a communication from the examining division
31.01.2020Despatch of a communication from the examining division (Time limit: M04)
14.09.2020Reply to a communication from the examining division
17.12.2020Communication of intention to grant the patent
29.04.2021Application deemed to be withdrawn, date of legal effect  [2021/40]
21.05.2021Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time  [2021/40]
Parent application(s)   TooltipEP05732613.4  / EP1732548
Divisional application(s)EP21170762.5  / EP3922248
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
14.09.2020Request for further processing filed
14.09.2020Full payment received (date of receipt of payment)
Request granted
21.09.2020Decision despatched
The application is deemed to be withdrawn due to failure to reply to the examination report
01.11.2019Request for further processing filed
01.11.2019Full payment received (date of receipt of payment)
Request granted
11.11.2019Decision despatched
The application is deemed to be withdrawn due to failure to reply to the examination report
06.09.2018Request for further processing filed
06.09.2018Full payment received (date of receipt of payment)
Request granted
14.09.2018Decision despatched
The application is deemed to be withdrawn due to failure to reply to the examination report
21.03.2016Request for further processing filed
21.03.2016Full payment received (date of receipt of payment)
Request granted
31.03.2016Decision despatched
The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report
21.12.2012Request for further processing filed
21.12.2012Full payment received (date of receipt of payment)
Request granted
21.01.2013Decision despatched
Fees paidRenewal fee
26.09.2011Renewal fee patent year 03
26.09.2011Renewal fee patent year 04
26.09.2011Renewal fee patent year 05
26.09.2011Renewal fee patent year 06
26.09.2011Renewal fee patent year 07
25.04.2012Renewal fee patent year 08
29.04.2013Renewal fee patent year 09
28.04.2014Renewal fee patent year 10
27.04.2015Renewal fee patent year 11
27.04.2016Renewal fee patent year 12
27.04.2017Renewal fee patent year 13
27.04.2018Renewal fee patent year 14
29.04.2019Renewal fee patent year 15
27.04.2020Renewal fee patent year 16
27.04.2021Renewal fee patent year 17
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[X] IE82916  (ELAN CORP PLC)
 [X]   BEVER C T: "THE CURRENT STATUS OF STUDIES OF AMINOPYRIDINES IN PATIENTS WITH MULTIPLE SCLEROSIS", ANNALS OF NEUROLOGY, BOSTON, US, vol. 36, 1 January 1994 (1994-01-01), pages S118 - S121, XP000653261, ISSN: 0364-5134

DOI:   http://dx.doi.org/10.1002/ana.410360728
 [X]   BEVER C T JR ET AL: "The effects of 4-aminopyridine in multiple sclerosis patients: Results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial", NEUROLOGY, LIPPINCOTT WILLIAMS & WILKINS, PHILADELPHIA, US, vol. 44, no. 6, 1 June 1994 (1994-06-01), pages 1054 - 1059, XP009115521, ISSN: 0028-3878
 [X]   SCHWID S R ET AL: "Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis", NEUROLOGY, LIPPINCOTT WILLIAMS & WILKINS, PHILADELPHIA, US, vol. 48, no. 4, 1 April 1997 (1997-04-01), pages 817 - 821, XP009115522, ISSN: 0028-3878
 [X]   VAN DIEMEN H A M ET AL: "THE EFFECT OF 4 AMINOPYRIDINE ON CLINICAL SIGNS IN MULTIPLE SCLEROSIS A RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND CROSS-OVER STUDY", ANNALS OF NEUROLOGY, vol. 32, no. 2, 1992, pages 123 - 130, XP002524401, ISSN: 0364-5134

DOI:   http://dx.doi.org/10.1002/ana.410320203
by applicantUS56089404
 US2004008101
 US1082804
 US5952357
   BLIGHT, A.R.: "Axonal physiology of chronic spinal cord injury in the cat: intracellular recording in vitro", NEUROSCIENCE, vol. 10, 1983, pages 1471 - 1486, XP024368464, DOI: doi:10.1016/0306-4522(83)90128-8

DOI:   http://dx.doi.org/10.1016/0306-4522(83)90128-8
   BLIGHT, A.R.: "Effect of 4-aminopyridine on axonal conduction-block in chronic spinal cord injury", BRAIN RES. BULL., vol. 22, 1989, pages 47 - 52, XP024388974, DOI: doi:10.1016/0361-9230(89)90126-3

DOI:   http://dx.doi.org/10.1016/0361-9230(89)90126-3
   BLIGHT, A.R., GRUNER, J.A.: "Augmentation by 4-aminopyridine of vestibulospinal free fall responses in chronic spinal- injured cats", J. NEUROL. SCI., vol. 82, 1987, pages 145 - 159, XP024296563, DOI: doi:10.1016/0022-510X(87)90014-1

DOI:   http://dx.doi.org/10.1016/0022-510X(87)90014-1
   BLIGHT, A.R.: "The effects of 4-aminopyridine on neurological deficits in chronic cases of traumatic spinal cord injury in dogs: a phase I clinical trial", J. NEUROTRAUMA, vol. 8, 1991, pages 103 - 119
   HAYES ET AL.: "Effects of intravenous 4-aminopyridine on neurological function in chronic spinal cord injured patients: preliminary observations", PROC. IBRO WORLD CONF. NEUROSCI., pages 345 1991
   KEITH C. HAYES, PATRICK J. POTTER, ROBERT R. HANSEBOUT, JOANNE M. BUGARESTI, JANE T. C. HSIEH, SERA NICOSIA, MITCHELL A. KATZ, AND, CLINICAL NEUROPHARMACOLOGY, vol. 26, no. 4, 2003, pages 185 - 192
   T. HIGUCHI, V. STELLA: "Pro-drugs as Novel Delivery Systems", A.C.S. SYMPOSIUM SERIES, vol. 14
   "Bioreversible Carriers in Drug Design", 1987, AMERICAN PHARMACEUTICAL ASSOCIATION AND PERGAMON PRESS
   S.M. BARGE ET AL.: "Pharmaceutical Salts", J. PHARM. SCI., vol. 66, 1977, pages 1 - 19
other  "RULES AND RELATED MATTERS", SEC NEWS DIGEST ISSUE 2003-186, 30 September 2003 (2003-09-30), XP055424855, Retrieved from the Internet
   GOODMAN ET AL.: "Placebo-controlled double-blinded dose ranging study of fampridine-SR in multiple sclerosis", POSTER - 18TH CONGRESS OF THE EUROPEAN COMMITTEE FOR THE TREATMENT AND RESEARCH IN MULTIPLE SCLEROSIS, 18 September 2002 (2002-09-18) - 21 September 2002 (2002-09-21), XP055424868
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.